Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies.
Ther Apher Dial
; 26(6): 1289-1295, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1764858
ABSTRACT
BACKGROUND:
Low-density lipoprotein apheresis is not specific to lipoproteins but removes immunoglobulins as well. It remains elusive, whether protective SARS-CoV-2 antibodies after vaccination from COVID-19 are eliminated as well.METHODS:
A cross-sectional case-control study on 55 patients undergoing weekly lipoprotein apheresis and 21 patients with comparable comorbidities and epidemiology not undergoing apheresis. SARS-CoV-2 IgG was assessed in all patients prior to apheresis and in 38 patients both before and after apheresis.RESULTS:
SARS-CoV-2 IgG concentrations before a session of lipoprotein apheresis were comparable to control patients not undergoing apheresis(1727 IU/ml, IQR 365-2500) vs. 1652 IU/ml,(IQR408.8-2500), p = 0.78). SARS-CoV-2 IgG concentrations were reduced by lipoprotein apheresis from 1656 IU/ml(IQR 540.5-2500) prior to 1305 IU/ml (IQR 449-2500) afterwards(p < 0.0001).CONCLUSION:
Lipoprotein apheresis removes SARS-CoV-2 IgG. The average elimination rate was 21.2%. In the present population of patients undergoing apheresis once weekly, however, the elimination did not lead to inferior concentrations compared to patients not undergoing lipoprotein apheresis.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Component Removal
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Ther Apher Dial
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
1744-9987.13842
Similar
MEDLINE
...
LILACS
LIS